Pathology and pathogenesis of portal venopathy in idiopathic portal hypertension: Hints from systemic sclerosis

Hepatology Research

Volumn 39, Issue 10, 2009, Pages 1023-1031

  Nakanuma, Yasuni ^a   Sato, Yasunori ^a   Kiktao, Azusa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Elastin; Phlebosclerosis; Portal hypertension; Portal vein; TGF

Indexed keywords

CALVASCULIN; CD34 ANTIGEN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; SMAD PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DISEASE ASSOCIATION; HUMAN; LIVER ATROPHY; LIVER FIBROSIS; MESENCHYME; MICROVASCULATURE; MYOFIBROBLAST; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BLOOD VESSEL; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; VEIN INSUFFICIENCY;

EID: 73849088457     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00555.x     Document Type: Article

References (54)

1. Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertention with an emphasis of the liver. Pathol Res Pract 2001; 197: 65-76.
2. Dhiman RK, Chawla Y, Vasishta RK et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and review of the literature. J Gastroenterol Hepatol 2002; 17: 6-16.
3. Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertention and its pathology. Semin Liver Dis 1996; 22: 59-72.
4. Tsuneyama K, Ohba K, Zen Y et al. A comparative histological and morphometric study of vascular changes in idiopathic portal hypertension and alcoholic fibrosis/cirrhosis. Histopathology 2003; 43: 55-61.
5. Tsuneyama K, Kouda W, Nakanuma Y. Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunohistochemical study. Pathol Res Pract 2002; 198: 597-603.
6. Nakanuma Y, Hoso M, Sasaki M et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28: 195-204.
7. Dumortier J, Bizollon T, Scoazec JY et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol 2001; 36: 417-22.
8. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham S.C. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11: 627-34.
9. Saito K, Nakanuma Y, Takegoshi K et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 1993; 40: 163-6.
10. Tsuneyama K, Harada K, Katayanagi K et al. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol 2002; 17: 217-23.
11. du Bois R.M. Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc 2007; 4: 434-8.
12. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
13. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
14. Nakanuma Y, Hoso M, Sanzen T, Sasaki M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 1997; 38: 552-70.
15. Terada T, Nakanuma Y. Development of human peribiliary capillary plexus: a lectin-histochemical and immunohistochemical study. Hepatology 1993; 18: 529-36.
16. Nakanuma Y, Kouda W, Nakano T, Uneno K, Tachibana S, Araki I. A case report of early idiopathic portal hypertension. Pathol Res Pract 2001; 197: 759-63.
17. Terada T, Nakanuma Y, Obata H. HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med 1991; 115: 993-7.
18. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. Expression of TGF-beta 1-beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 1999; 21: 13-22.
19. Morikawa H, Tamori A, Nishiguchi S et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13: 240-5.
20. Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20.
21. Gabrielli A, Di Loreto C, Taborro R et al. Immunohistochemical localization of intracellular and extracellular associated TGF-b in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993; 68: 340-9.
22. Hasegawa M, Sato S, Takehara K. Augumented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004; 296: 89-93.
23. Duncan MR, Frazier KS, Abramson S et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999; 13: 1774-86.
24. Bradham DM, Igarashi A, Potter RL, Grotendorst G.R. Connective tissue growth factor: a cystein-rich mitogen secreted by human vascular endothelial cells is related to the SRC induced immediate early gene product CEF-10. J Cell Biol 1991; 114: 1285-94.
25. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. Invest Dermatol 1996; 106: 729-33.
26. Igarashi A, Nashiro K, Kikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
27. Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
28. Nakanuma Y, Nonomura A, Hayashi M et al. Pathology of the liver in "idiopathic portal hypertension" associated with autoimmune disease. The Ministry of Health and Welfare Disorders of Portal Circulation Research Committee. Acta Pathol Jpn 1989; 39: 586-92.
29. Sato Y, Sawada S, Kozaka K et al. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci 2007; 52: 1987-94.
30. Tsuneyama K, Kouda W, Nakanuma Y. Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunochemical study. Pathol Res Pract 2002; 198: 597-603.
31. Igarashi A, Nashiro K, Kikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
32. Tamatani T, Kobayashi H, Tezuka K et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998; 251: 748-52.
33. Rachfal AW, Brigstock D.R. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26: 1-9.
34. Abou-Shady M, Friess H, Zimmermann A et al. Connective tissue growth factor in human liver cirrhosis. Liver 2000; 20: 296-304.
35. Needleman BW, Choi J, Burrows-Menzu A, Fontana J.A. Secretion and binding of transforming growth factor-b by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990; 33: 650-3.
36. Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon R.C. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000; 32: 754-61.
37. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006; 52: 1815-17.
38. Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-Mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
39. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007; 67: 10123-8.
40. Arciniegas E, Frid MG, Douglas IS, Stenmark K.R. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1-8.
41. Karasek M.A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med Hypotheses 2007; 68: 650-5.
42. Chaudhuri V, Zhou L, Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis. J Cutan Pathol 2007; 34: 146-53.
43. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGF{beta}-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008; 121: 3317- 24.
44. Gaca MD, Zhou X, Benyon R.C. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinaseactivated receptors. J Hepatol 2002; 36: 362-9.
45. Ozaki S, Sato Y, Yasoshima M, Harada K, Nakanuma Y. Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis. Liver Int 2005; 25: 817-28.
46. Tuchweber B, Desmouliere A, Bochaton-Piallat M L, Rubbia-Brandt L, Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest 1996; 74: 265- 78.
47. Sato Y, Harada K, Ozaki S et al. Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol 2007; 171: 1859-71.
48. Verrecchia F, Mauviel A, Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 2006; 5: 563-9.
49. Nanji AA, Tahan SR, Golding M, Khwaja S, Rahemtulla A, Laiani E.N. Role of transforming growth factor-beta1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease. Am J Pathol 1996; 148: 739-47.
50. Ramm GA, Nair VG, Bridle KR, Shepherd RW, Crawford D.H. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. Am J Pathol 1998; 153: 527-35.
51. Akahoshi T, Hashizume M, Tanoue K et al. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J Gastroenterol Hepatol 2002; 17: 59-65.
52. Sawada S, Sato Y, Aoyama H, Harada K, Nakanuma Y. Pathological study of idiopathic portal hypertension with an emphasis on cause of death based on records of Annuals of Pathological Autopsy Cases in Japan. J Gastroenterol Hepatol 2007; 22: 204-9.
53. Ichimura S, Sasaki R, Takemura Y et al. The prognosis of idiopathic portal hypertension in Japan. Intern Med 1993; 32: 441-4.
54. Sato Y, Sawada S, Nakanuma Y. Fibulin-5 is involved in phlebosclerosis of major portal vein branches associated with elastic fiber deposition in idiopathic portal hypertension Hepatol Res 2008; 38: 166-73.